Privaris

Pharvaris is a clinical-stage biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE) and other bradykinin-mediated diseases. The company's lead candidate, deucrictibant, is a potent and selective oral bradykinin B2 receptor antagonist designed to provide a convenient alternative to current injectable treatments. Pharvaris is currently advancing deucrictibant through Phase 3 clinical trials for both the on-demand treatment of acute HAE attacks and the long-term prophylaxis of the condition. By leveraging its expertise in bradykinin biology, the company aims to improve the quality of life and treatment options for patients living with rare angioedema disorders.